Subject terms
pancreatic ductal carcinoma, PDAC
PANCREATIC DUCTAL ADENOCARCINOMA, DISEASE, RECURRENCE
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patientsA phase I clinical trial of an adjuvant personalized mRNA neoantigen vaccine, autogene cevumeran, in patients with pancreatic ductal carcinoma demonstrates that the vaccine can induce T cell activity that may correlate with delayed recurrence of disease.